Cargando…

Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension

BACKGROUND: Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH). However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers of thrombogenesis and fibrinolysis in patients with IPAH. METHODS: We studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kopeć, Grzegorz, Moertl, Deddo, Steiner, Sabine, Stępień, Ewa, Mikołajczyk, Tomasz, Podolec, Jakub, Waligóra, Marcin, Stępniewski, Jakub, Tomkiewicz-Pająk, Lidia, Guzik, Tomasz, Podolec, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847115/
https://www.ncbi.nlm.nih.gov/pubmed/24312667
http://dx.doi.org/10.1371/journal.pone.0082628
_version_ 1782293542841876480
author Kopeć, Grzegorz
Moertl, Deddo
Steiner, Sabine
Stępień, Ewa
Mikołajczyk, Tomasz
Podolec, Jakub
Waligóra, Marcin
Stępniewski, Jakub
Tomkiewicz-Pająk, Lidia
Guzik, Tomasz
Podolec, Piotr
author_facet Kopeć, Grzegorz
Moertl, Deddo
Steiner, Sabine
Stępień, Ewa
Mikołajczyk, Tomasz
Podolec, Jakub
Waligóra, Marcin
Stępniewski, Jakub
Tomkiewicz-Pająk, Lidia
Guzik, Tomasz
Podolec, Piotr
author_sort Kopeć, Grzegorz
collection PubMed
description BACKGROUND: Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH). However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers of thrombogenesis and fibrinolysis in patients with IPAH. METHODS: We studied 27 consecutive patients (67% female) with IPAH aged 50.0 years (IQR: 41.0 - 65.0) and 16 controls without pulmonary hypertension. Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) complexes were measured to assess thrombogenesis; tissue-type plasminogen activator (tPA) antigen and plasmin-anti-plasmin complex to characterize activation of fibrinolysis; plasminogen activator inhibitor 1 (PAI-1) to measure inhibition of fibrinolysis; and endothelin-1 (ET-1) and interleukin-6 (IL-6) to assess endothelial activation and systemic inflammation, respectively. In addition, in treatment-naive IPAH patients these markers were assessed after 3 months of PAH-specific therapies. RESULTS: TPA (10.1[6.8-15.8] vs 5.2[3.3-7.3] ng/ml, p<0.001), plasmin-anti-plasmin (91.5[60.3-94.2] vs 55.8[51.1-64.9] ng/ml, p<0.001), IL-6 (4.9[2.5-7.9] vs 2.1[1.3-3.8] pg/ml, p=0.001) and ET-1 (3.7 [3.3-4.5] vs 3.4[3.1-3.5], p= 0.03) were higher in patients with IPAH than in controls. In IPAH patients plasmin-anti-plasmin and tPA correlated positively with IL-6 (r=0.39, p=0.04 and r=0.63, p<0.001, respectively) and ET-1 (r=0.55, p=0.003 and r=0.59, p=0.001, respectively). No correlation was found between tPA or plasmin-anti-plasmin and markers of thrombogenesis. Plasmin-anti-plasmin decreased after 3 months of PAH specific therapy while the other markers remained unchanged. CONCLUSIONS: In the present study we showed that markers of fibrynolysis were elevated in patients with IPAH however we did not find a clear evidence for increased thrombogenesis in this group of patients. Fibrinolysis, inflammation, and endothelial activation were closely interrelated in IPAH.
format Online
Article
Text
id pubmed-3847115
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38471152013-12-05 Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension Kopeć, Grzegorz Moertl, Deddo Steiner, Sabine Stępień, Ewa Mikołajczyk, Tomasz Podolec, Jakub Waligóra, Marcin Stępniewski, Jakub Tomkiewicz-Pająk, Lidia Guzik, Tomasz Podolec, Piotr PLoS One Research Article BACKGROUND: Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH). However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers of thrombogenesis and fibrinolysis in patients with IPAH. METHODS: We studied 27 consecutive patients (67% female) with IPAH aged 50.0 years (IQR: 41.0 - 65.0) and 16 controls without pulmonary hypertension. Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) complexes were measured to assess thrombogenesis; tissue-type plasminogen activator (tPA) antigen and plasmin-anti-plasmin complex to characterize activation of fibrinolysis; plasminogen activator inhibitor 1 (PAI-1) to measure inhibition of fibrinolysis; and endothelin-1 (ET-1) and interleukin-6 (IL-6) to assess endothelial activation and systemic inflammation, respectively. In addition, in treatment-naive IPAH patients these markers were assessed after 3 months of PAH-specific therapies. RESULTS: TPA (10.1[6.8-15.8] vs 5.2[3.3-7.3] ng/ml, p<0.001), plasmin-anti-plasmin (91.5[60.3-94.2] vs 55.8[51.1-64.9] ng/ml, p<0.001), IL-6 (4.9[2.5-7.9] vs 2.1[1.3-3.8] pg/ml, p=0.001) and ET-1 (3.7 [3.3-4.5] vs 3.4[3.1-3.5], p= 0.03) were higher in patients with IPAH than in controls. In IPAH patients plasmin-anti-plasmin and tPA correlated positively with IL-6 (r=0.39, p=0.04 and r=0.63, p<0.001, respectively) and ET-1 (r=0.55, p=0.003 and r=0.59, p=0.001, respectively). No correlation was found between tPA or plasmin-anti-plasmin and markers of thrombogenesis. Plasmin-anti-plasmin decreased after 3 months of PAH specific therapy while the other markers remained unchanged. CONCLUSIONS: In the present study we showed that markers of fibrynolysis were elevated in patients with IPAH however we did not find a clear evidence for increased thrombogenesis in this group of patients. Fibrinolysis, inflammation, and endothelial activation were closely interrelated in IPAH. Public Library of Science 2013-12-02 /pmc/articles/PMC3847115/ /pubmed/24312667 http://dx.doi.org/10.1371/journal.pone.0082628 Text en © 2013 Kopeć et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kopeć, Grzegorz
Moertl, Deddo
Steiner, Sabine
Stępień, Ewa
Mikołajczyk, Tomasz
Podolec, Jakub
Waligóra, Marcin
Stępniewski, Jakub
Tomkiewicz-Pająk, Lidia
Guzik, Tomasz
Podolec, Piotr
Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension
title Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension
title_full Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension
title_fullStr Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension
title_full_unstemmed Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension
title_short Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension
title_sort markers of thrombogenesis and fibrinolysis and their relation to inflammation and endothelial activation in patients with idiopathic pulmonary arterial hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847115/
https://www.ncbi.nlm.nih.gov/pubmed/24312667
http://dx.doi.org/10.1371/journal.pone.0082628
work_keys_str_mv AT kopecgrzegorz markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT moertldeddo markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT steinersabine markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT stepienewa markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT mikołajczyktomasz markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT podolecjakub markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT waligoramarcin markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT stepniewskijakub markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT tomkiewiczpajaklidia markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT guziktomasz markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension
AT podolecpiotr markersofthrombogenesisandfibrinolysisandtheirrelationtoinflammationandendothelialactivationinpatientswithidiopathicpulmonaryarterialhypertension